Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Assets for 4 consecutive years, with $104.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 39.15% to $104.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $104.8 million, a 39.15% increase, with the full-year FY2024 number at $76.2 million, down 20.0% from a year prior.
  • Assets was $104.8 million for Q3 2025 at Orchestra BioMed Holdings, up from $42.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $161.6 million in Q2 2022 to a low of $42.8 million in Q2 2025.
  • A 4-year average of $98.3 million and a median of $95.2 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: surged 69.5% in 2023, then plummeted 42.5% in 2024.
  • Orchestra BioMed Holdings' Assets stood at $95.6 million in 2022, then decreased by 0.38% to $95.2 million in 2023, then dropped by 20.0% to $76.2 million in 2024, then soared by 37.59% to $104.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Assets are $104.8 million (Q3 2025), $42.8 million (Q2 2025), and $59.1 million (Q1 2025).